Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 3/20 | 0.32 |
| ▸ | CDC25B | P30305 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15386624 | 0.82 | PARP1 (0.34) | HCAR2KMT2ATSHRNR1H4PARP1 | |
| SCHEMBL12500050 | 0.80 | HCAR2 (0.36) | HCAR2KMT2ATSHRPARP1 | |
| SCHEMBL15385520 | 0.79 | PARP1 (0.31) | HCAR2KMT2APARP1 | |
| SCHEMBL15385479 | 0.76 | HCAR2 (0.42) | HCAR2KMT2ATSHRPARP1 | |
| SCHEMBL12498760 | 0.75 | HCAR2 (0.61) | HCAR2KMT2ATSHR | |
| SCHEMBL12498279 | 0.73 | KMT2A (0.42) | HCAR2KMT2ATSHRPARP1 | |
| SCHEMBL12499437 | 0.72 | KDM4E (0.48) | KMT2ATSHR | |
| SCHEMBL3503658 | 0.69 | BRD4 (0.50) | KMT2ATSHR | |
| SCHEMBL12698141 | 0.65 | PARP1 (0.42) | PARP1 | |
| SCHEMBL31326941 | 0.65 | KMT2A (0.34) | HCAR2KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916577-B2 | Tricyclic derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-12-23 | — | — | US | disclosed |
| US-20130302416-A1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130302416-A1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | CDK1, MAP3K1, MAP3K20 | HCAR2 2119/4885KMT2A 1071/4885TSHR 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.